The National Institute for Health and Care Excellence (NICE) has approved US biotech Celgene’s Imnovid (pomalidomide) in combination with dexamethasone for use in relapsed myeloma patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug is specifically approved for patients who have received at least two prior treatments, including Velcade and Revlimid.

Following the approval, the drug will now be immediately available for myeloma patients.

NICE centre for health technology evaluation director Carole Longson said: “Treating multiple myeloma can be difficult because the disease often relapses and drugs can stop working. Pomalidomide offers patients a clinically effective and well-tolerated oral treatment.”

See Also:

“It’s great news that our independent committee were able to recommend pomalidomide for routine use after updated data and a confidential discount were taken into account when reviewing our original decision on this drug.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In September 2015, Imnovid was turned down by NICE and delisted from the Cancer Drugs Fund.

"Pomalidomide is an effective treatment that will fill a major gap in the treatment pathway for patients at third relapse and beyond."

Myeloma UK chief executive Eric Low said: “Pomalidomide is an effective treatment that will fill a major gap in the treatment pathway for patients at third relapse and beyond.

In September 2013, the drug received its European licence from the European Medicines Agency (EMA).

It is from a class of drugs called immunomodulatory drugs, which work in a similar way to thalidomide and Revlimid.

Imnovid is already available for relapsed myeloma patients in Scotland and Wales and will be made available to others within three months of NICE issuing final guidance, expected in January next year.

Image: Pomalidomide is specifically approved for patients who have received at least two prior treatments, including Velcade and Revlimid. Photo: courtesy of Myeloma UK.